Variable | Training cohort (n = 1124) | Internal validation cohort (n = 482) | ||||
---|---|---|---|---|---|---|
dMMR (n = 273) | pMMR (n = 851) | p value | dMMR (n = 117) | pMMR (n = 365) | p value | |
Age | 54.0 (42.8, 64.0) | 60.0 (50.0, 68.0) | < 0.001 | 57.0 (44.7, 65.3) | 60.0 (51.0, 67.3) | 0.022 |
Gender | Â | Â | 0.762 | Â | Â | 0.241 |
 Male | 169 | 516 |  | 64 | 224 |  |
 Female | 104 | 335 | 53 | 141 |  | |
cT stage | Â | Â | 0.145 | Â | Â | 0.019 |
 1–2 | 3 | 19 |  | 3 | 14 |  |
 3 | 168 | 550 | 62 | 241 |  | |
 4a | 94 | 243 | 52 | 107 |  | |
 4b | 8 | 39 | 0 | 3 |  | |
cN stage |  |  | < 0.001 |  |  | 0.005 |
 0 | 69 | 250 |  | 17 | 89 |  |
 1 | 108 | 443 | 66 | 214 |  | |
 2 | 96 | 158 | 34 | 62 |  | |
Location |  |  | < 0.001 |  |  | < 0.001 |
 Right | 168 | 284 |  | 84 | 119 |  |
 Left | 105 | 567 | 33 | 246 |  | |
Tumor marker | Â | Â | Â | Â | Â | Â |
 CEA (IQR) | 12.1 (1.4, 4.5) | 80.3 (2.1, 13.0) | 0.164 | 10.6 (1.6, 4.3) | 23.7 (2.3, 11.1) | 0.241 |
 CA125 (IQR) | 19.4 (8.6, 17.8) | 26.3 (8.7, 21.8) | 0.017 | 17.1 (8.2, 17.3) | 32.6 (9.1, 23.4) | 0.120 |
 CA199 (IQR) | 150.9 (2.7, 20.2) | 536.4 (4.1, 30.1) | 0.247 | 27.0 (2.8, 14.8) | 156.4 (3.9, 24.3) | 0.243 |
 CA153 (IQR) | 10.4 (6.3, 13.0) | 10.4 (6.3, 12.2) | 0.990 | 9.1 (6.0, 12,1) | 10.4 (6.6, 12.2) | 0.202 |